Prediction of sudden cardiac death after myocardial infarction in the beta-blocking era  by Huikuri, Heikki V et al.
Prediction of Sudden Cardiac Death After
Myocardial Infarction in the Beta-Blocking Era
Heikki V. Huikuri, MD, FACC,* Jari M. Tapanainen, MD,* Kai Lindgren, MD,* Pekka Raatikainen, MD,*
Timo H. Ma¨kikallio, MD,* K. E. Juhani Airaksinen, MD,* Robert J. Myerburg, MD, FACC†
Oulu, Finland; and Miami, Florida
OBJECTIVES This study assessed the predictive power of arrhythmia risk markers after an acute myocardial
infarction (AMI).
BACKGROUND Several risk variables have been suggested to predict the occurrence of sudden cardiac death
(SCD), but the utility of these variables has not been well established among patients using
medical therapy according to contemporary guidelines.
METHODS A consecutive series of 700 patients with AMI was studied. The end points were total
mortality, SCD, and nonsudden cardiac death (non-SCD). Nonsustained ventricular tachy-
cardia (nsVT), ejection fraction (EF), heart rate variability, baroreflex sensitivity, signal-
averaged electrocardiogram (SAECG), QT dispersion, and QRS duration were analyzed (n
 675). Beta-blocking therapy was used by 97% of the patients at discharge and by 95% at
one and two years after AMI.
RESULTS During a mean (SD) follow-up of 43  15 months, 37 non-SCDs (5.5%) and 22 SCDs
(3.2%) occurred. All arrhythmia risk variables differed between the survivors and those with
non-SCD (e.g., the standard deviation of N-N intervals was 98  32 vs. 74  21 ms [p 
0.001] and the QRS duration was 103  22 vs.89  16 ms [p  0.001]). Sudden cardiac
death was weakly predicted only by reduced EF (0.40; p  0.05), nsVT (p  0.05), and
abnormal SAECG (p  0.05), but not by autonomic markers or standard ECG variables.
The positive predictive accuracy of EF, nsVT, and abnormal SAECG as predictors of SCD
was relatively low (8%, 12%, and 13%, respectively).
CONCLUSIONS The common arrhythmia risk variables, particularly the autonomic and standard ECG
markers, have limited predictive power in identifying patients at risk of SCD after AMI in the
beta-blocking era. (J Am Coll Cardiol 2003;42:652–8) © 2003 by the American College of
Cardiology Foundation
Data from various sources have shown that sudden cardiac
death (SCD) accounts for 50% of all subsequent cardiac
deaths among patients who have survived an acute myocar-
dial infarction (AMI), and that there is a specific time
dependence of SCD after AMI (1–6). Numerous studies
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have also suggested that certain arrhythmia risk variables
can specifically predict the occurrence of SCD after AMI
(7–15). Some of these risk markers have been suggested to
be useful for widespread screening of patients for the
candidacy of anti-arrhythmic interventions, such as place-
ment of an implantable cardioverter-defibrillator (ICD)
(7,15–18).
Most of the previous studies assessing the proportion and
time dependence of SCD risk, as well as estimating the
predictive power of various risk variables after AMI, have
been performed in the absence of optimal compliance to
beta-blocking therapy (7–17), which may have a major
influence on the prediction and epidemiologic pattern of
SCD (19). This single-center, prospective study was de-
signed to assess the power of the risk predictors of SCD and
arrhythmia events in a consecutive series of patients surviv-
ing an AMI and with an optimal compliance to beta-
blocker therapy.
Patient population. A single-center, prospective study—
the Multiple Risk Factor Analysis Trial (MRFAT)—was
started in 1996 in the Division of Cardiology, University of
Oulu, Finland. The aim was to estimate the predictive
power of several noninvasive arrhythmia and clinical risk
markers for SCD and arrhythmia events among patients
who had survived an AMI. A consecutive series of patients
with AMI was included in the study. The patients were
recruited to participate during the first seven days after the
diagnosis of AMI, which was confirmed by using the
contemporary guidelines at the beginning of the study (20).
The exclusion criteria were unstable angina at recruitment,
dementia, alcoholism, drug abuse, or any other condition
that could impair the capacity for informed consent. The
qualifying diagnosis of the patients have previously been
described in detail in a smaller pilot study (20). A total of
700 consecutive patients (182 females and 518 males; mean
age 62  10 years) with AMI fulfilled the inclusion criteria.
Beta-blocking treatment was prescribed to all patients at
the time of discharge from the hospital. The dose of
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beta-blocker therapy was adjusted to achieve a resting heart
rate between 50 and 60 beats/min, and a special emphasis
was paid to long-term compliance with the beta-blocking
medication. In the total study population, beta-blocking
drugs were used by 654 (97%) of 675 patients at discharge,
620 (95%) of 652 patients at one year, and 577 (95%) of
609 patients at two years after AMI. Other cardiac medi-
cations were prescribed by the primary physicians of the
patients, and revascularization therapy was used according
to contemporary guidelines (21). All patients were required
to give written, informed consent, and the study was
approved by the Ethical Committee of the institution.
Risk factor analyses. All risk factor analytical techniques
have been previously described in detail (14,20). Left
ventricular systolic function was measured with two-
dimensional echocardiography between three and seven
days after AMI. Ejection fraction (EF) 0.40 was a
predefined cut-off point in risk stratification (20).
Baroreflex sensitivity (BRS) was measured between
days 5 and 14 with a phenylephrine method (20). A value
3.0 ms/mm Hg was defined as abnormal (7,20). A 24-h
electrocardiographic (ECG) recording was obtained with an
Oxford Medilog system (Oxford Medilog 4500, Oxford
Medical Ltd., London, England) between days 5 and 14
after AMI. The number of episodes of nonsustained ven-
tricular tachycardia (nsVT) and the number of ventricular
premature beats were counted. The standard deviation of all
N-N intervals measured from the 24-h recording was
chosen as an index of heart rate variability (HRV), and a
value 70 ms was defined as abnormal (20,22).
QT intervals and QRS durations were measured between
days 5 and 14 from two cycles on a standard 12-lead surface
ECG recorded at a speed of 50 mm/ms (14). A QT
dispersion value 90 ms and a QRS duration 120 ms
were considered abnormal (20). The signal-averaged ECG
(SAECG) was recorded between days 5 and 14 using the
LP Plus system (Fidelity Medical Ltd., Haifa, Israel) (20).
The presence of late potentials was defined as described
previously (20,23).
Follow-up and end points. The patients or their families
were contacted via telephone at 6, 24, 36, 48, and 60
months after AMI, and the patients had a clinical visit at 12
months after AMI. In cases of death, the reasons for death
were verified from the hospital and autopsy records and
from either the primary physician or those who had wit-
nessed the death. Two independent end point commit-
tees—one at the University of Oulu and the other at the
University of Miami—defined the mode of deaths. Cardiac
deaths were defined as sudden or nonsudden. Cardiac death
was defined as sudden if it was: 1) a witnessed death
occurring within 60 min from the onset of new symptoms,
unless a cause other than cardiac was obvious; 2) un-
witnessed death (24 h) in the absence of preexisting,
progressive circulatory failure or other causes of death; or
3) death during attempted resuscitation (19). In addition to
the clinical definition of SCD, probable ventricular tachy-
arrhythmia events were separately defined as events with a
high probability of prevention by the ICD. These events
were defined as: 1) successful resuscitation from sustained
ventricular or fibrillation; or 2) probable arrhythmic death.
Probable arrhythmic death was defined as SCD with veri-
fied ECG recordings of ventricular tachycardia or fibrilla-
tion at the time of resuscitation, or a witnessed instanta-
neous death without evidence of a nonarrhythmic cause of
death at autopsy.
Statistical analysis. The data were analyzed using the
SPSS software (version 9.0, SPSS Inc., Chicago, Illinois).
Comparisons of the baseline characteristics between the
groups were performed with analysis of variance with
Bonferroni post-hoc analysis and with the chi-square test
for categorical variables. Analysis of variance was performed
by including survivors in the non-SCD and SCD groups
and survivors in the non-SCD and arrhythmia event groups
separately. Hazard ratios and 95% confidence intervals were
calculated for each categorical variable by using predefined
cut-off values in the Cox regression model. To estimate the
independent predictive power of the variables, each arrhyth-
mia risk variable was included in the Cox proportional
hazards regression analyses after stratification with the
clinical factors. Kaplan-Meier estimates of the distribution
of times from baseline to total mortality, cardiac death,
SCD, and non-SCD were computed. A p value 0.05 was
considered statistically significant.
RESULTS
Mortality and time distribution of events during follow-
up. Twenty-five of the enrolled patients died during their
hospital stay after AMI, and 675 who were discharged alive
were included in the long-term follow-up sample. During a
mean follow-up of 43  15 months (range 30 to 60), total
mortality was 15.0%; among these, 59 (8.7%) were cardiac
deaths and 42 (6.2%) were noncardiac deaths. Among the
cardiac deaths, 37 (5.5%) were nonsudden and 22 (3.3%;
37% of cardiac deaths) were sudden. Arrhythmia events
occurred in 17 patients (2.5%).
Figure 1 demonstrates the cumulative event rates for total
mortality, cardiac deaths, non-SCDs, and SCDs during
follow-up. The temporal distribution of events did not differ
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from that expected from previous studies for all-cause
mortality. In addition, the majority of non-SCDs (68%)
occurred during the first 18 months after AMI. However,
the incidence and temporal distribution of SCDs (14%) was
significantly lower during the early time period (p 0.001).
Similarly, only 3 of the 17 arrhythmia events occurred
during the first 18 months after AMI.
Differences in baseline clinical data. The clinical data of
survivors and those who experienced non-SCD or SCD or
arrhythmia events are shown in Table 1. There were several
differences in the baseline clinical characteristics between
those who were alive and those who had died due to a
cardiac cause, either sudden or nonsudden. For example, a
high proportion of the patients who experienced either
SCD or non-SCD had diabetes. The only significant
difference between the patients who died nonsuddenly or
suddenly due to a cardiac cause was in the New York Heart
Association (NYHA) functional class—class I being more
common among those who died suddenly (55%) than
among those who had a non-SCD (24%; p  0.05).
Patients who experienced a probable tachyarrhythmia event
were also younger and more commonly in NYHA class I
(76%; p  0.001 vs. non-SCD).
Arrhythmia risk variables. The mean values for arrhyth-
mia risk variables are shown in Table 2 and Figure 2. All
arrhythmia risk variables differed between the survivors and
those who had a non-SCD. The patients who died suddenly
did not differ from those who remained alive in terms of any
of these variables, except that nsVT was more commonly
observed on Holter recordings and the EF was lower among
those who experienced SCD (p  0.048) or an arrhythmia
event (p  0.023).
The hazard ratios of each categorized arrhythmia risk
variable with predefined cut-off values are shown in Table 3.
On univariate analysis, SCD and arrhythmia events were
predicted by reduced EF, nsVT, and abnormal SAECG.
After including clinical variables as co-variates, such as age,
functional class, diabetes, revascularization, and use of
beta-blocking medication, the same variables still predicted
SCD. The numbers of patients with true-positive, false-
negative, true-negative, and false-positive test results are
shown in Table 4. The positive predictive accuracy values of
low EF, nsVT, and abnormal SACEG in predicting SCD
(8%, 12%, and 13%, respectively) were lower than those of
non-SCD (15%, 15%, and 18%, respectively).
DISCUSSION
Two main differences were observed in this study among the
post-AMI patients with a good adherence to beta-blocking
therapy, compared with earlier studies. First, the common
arrhythmia risk markers provided only limited predictive
Figure 1. Cumulative event rates for total mortality and cardiac mortality (left panel) and non-sudden cardiac death (SCD) and SCD mortality (right
panel). The proportion of patients who died nonsuddenly was higher than that of the patients who died suddenly, particularly during the first 18 months
after acute myocardial infarction.
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power on the risk of future SCD or arrhythmia events.
Many risk variables that were considered to provide infor-
mation on the risk of SCD appeared to better predict the
occurrence of non-SCD in this population, possibly because
of a specific benefit of beta-blocking therapy on SCD,
leaving non-SCD risk relatively unopposed early after AMI.
Secondly, the epidemiologic pattern of SCD was different
from that reported in previous studies (2–15). Arrhythmia
events or SCDs did not concentrate early after the index
event, but most of them occurred more than 18 months
after AMI.
Prediction of SCD after AMI. Although several clinical
and arrhythmia risk markers were associated with an in-
creased risk of cardiac mortality in this study, they did not
Table 1. Clinical Characteristics of the Study Population
Survivors
(n  574)
Non-SCD
(n  37)
SCD
(n  22)
Arrhythmia Event
(n  17)
Clinical features
Age (yrs) 61  10 71  7* 67  8† 63  8§
Gender (F/M) 137/437 11/26 9/13‡ 4/13
Smokers 182 (32%) 4 (11%)‡ 8 (36%)‡ 8 (47%)§
Previous MI 107 (19%) 17 (46%)* 6 (27%) 4 (24%)
Previous CHF 48 (8%) 17 (46%)* 7 (32%)* 5 (29%)‡
Diabetes 116 (20%) 17 (46%)* 13 (59%)* 8 (47%)*
Previous CABG 27 (5%) 7 (19%)† 4 (18%)† 4 (24%)
Features of MI
Anterior MI 250 (44%) 25 (68%)† 16 (72%)† 12 (70%)‡
Q-wave MI 300 (51%) 9 (24%)† 10 (45%)‡ 10 (59%)
Thrombolysis 285 (50%) 6 (16%)* 5 (23%)† 6 (35%)
PTCA or CABG before discharge 145 (25%) 4 (11%) 1 (5%) 1 (6%)
AF at discharge 12 (2%) 5 (14%)* 1 (5%) 3 (18%)†
Maximum CK-MB (U/l) 174  188 112  127 177  195 235  210
Killip class 3 or 4 47 (8%) 16 (43%)* 6 (27%)* 4 (25%)
NYHA class II or III at discharge 149 (26%) 28 (77%)* 10 (45%)†¶ 4 (25%)
Medication at discharge
Aspirin or warfarin 549 (96%) 33 (89%) 19 (100%) 17 (100%)
Beta-blockers 555 (97%) 35 (95%) 22 (100%) 16 (94%)
Statins 221 (39%) 4 (11%) 7 (32%) 7 (41%)
ACE inhibitors/AT II blockers 210 (37%) 22 (59%)‡ 13 (59%)‡ 11 (65%)‡
Calcium channel blockers 40 (7%) 7 (19%) 1 (5%) 2 (12%)
Digoxin 17 (3%) 15 (41%)* 1 (5%)¶ 2 (12%)
Diuretic 102 (18%) 29 (78%)* 13 (59%)* 8 (47%)¶
*p  0.001, †p  0.01, and ‡p  0.05 compared with survivors. §p  0.01, ¶p  0.05, and p  0.001 compared with patients
who experienced a nonsudden cardiac death (non-SCD) during follow-up. Data are presented as the mean value  SD.
ACE  angiotensin-converting enzyme; AF  atrial fibrillation; AT II  angiotensin II receptor; CABG  coronary artery
bypass grafting; CHF  congestive heart failure; CK-MB  creatine kinase-MB fraction; MI  myocardial infarction; NYHA
 New York Heart Association; PTCA  percutaneous transluminal coronary angioplasty; SCD  sudden cardiac death.
Table 2. Arrhythmia Risk Variables
Survivors
(n  574)
Non-SCD
(n  37)
SCD
(n  22)
Arrhythmia Event
(n  17)
EF (%) 46  9 37  11* 41  11† 39  12†
Holter monitor
nsVT 24 (4%) 5 (14%)† 4 (18%)† 4 (24%)†
10 VPBs/h 72 (13%) 12 (32%)‡ 5 (23%) 3 (18%)
Autonomic markers
SDNN (ms) 98  32 74  21* 82  29 93  42
BRS (ms/mm Hg) 9.3  8.1 5.3  6.0† 8.2  12.3 8.7  13.8
ECG markers
QRS duration (ms) 89  16 103  22* 93  19 95  22
QT dispersion (ms) 74  39 91  33‡ 80  48 87  48
SAECG
QRS duration (ms) 98  18 116  25* 103  22 102  23
rms last 40 ms 47  33 44  33 49  44 43  33
Duration 40 V/ms 29  10 29  15 36  20‡ 33  14
*p  0.001, †p  0.05, and ‡p  0.01 compared with survivors. Data are presented as the mean value  SD.
BRS  baroreflex sensitivity; ECG  electrocardiogram; EF  ejection fraction; nsVT  nonsustained ventricular
tachycardia; rms  root mean square; SAECG  signal-averaged electrocardiogram; SCD  sudden cardiac death; SDNN 
standard deviation of N-N intervals; VPBs  ventricular premature beats.
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identify risk for a specific type of cardiac death, either
sudden or nonsudden. Similarities in the risk profile be-
tween the patients who died suddenly or nonsuddenly imply
that there are common factors predisposing to both SCD
and non-SCD, with severe coronary artery disease and left
ventricular dysfunction probably being the most important.
The only arrhythmia risk variables that were able to
separate the patients who subsequently experienced SCD or
an arrhythmia event from survivors were reduced EF, nsVT,
and abnormal SAECG. However, the positive predictive
accuracy of even these variables was lower in the prediction
of SCD versus non-SCD. Patients who experienced an
arrhythmia event also had less severe functional impairment,
assessed by NYHA class, compared with those who had a
non-SCD, despite similar impairment of left ventricular
systolic function. This is in agreement with a recent trial
showing that a higher proportion of patients with less
functional impairment will die suddenly, whereas the ma-
jority of patients with advanced functional impairment will
experience a non-SCD (19).
In contrast to the present observations, previous studies
have suggested that the markers of autonomic nervous
function (7,12) and measurements from the standard 12-
lead ECG (4,13–15) specifically predict the risk of SCD or
arrhythmia events, alone or in combination with other
variables (7,12). The only obvious difference between the
previous studies and the present one is in the usage of
medication. For example, in the Autonomic Tone and
Reflexes After Myocardial Infarction (ATRAMI) trial,
showing that autonomic markers are powerful predictors of
SCD, only 20% of post-AMI patients were taking beta-
blocking medication (7). Beta-blocking drugs have signifi-
cant influences on both HRV and BRS (24,25) and also on
the incidence of SCD (19), perhaps explaining the lack of
predictive power of autonomic markers among patients who
are treated with continuous beta-blocking medication.
The proportion of patients receiving beta-blocking med-
ication has varied between 10% and 70% in previous
observational studies and randomized trials (4,7–18). Data
from several studies have convincingly shown that beta-
blocking medication specifically reduces the incidence of
SCDs in high-risk post-AMI populations (19,26–29). An
obvious explanation for the lack of predictive power of many
arrhythmia risk variables was the altered temporal distribu-
tion of SCD after AMI, because beta-blockers seem to
provide an increased benefit for the early occurrence of
SCD. Similarly, a recent randomized trial including patients
with a depressed EF and remote AMI (18) showed that in
the presence of effective therapy of heart failure, including
beta-blockers, the survival benefit of ICD therapy began
relatively late as compared with previous trials without
optimized medical therapy (16,17).
Figure 2. Mean (SD) ejection fraction (upper left panel), standard deviation of N-N intervals (SDNN) measured from 24-h Holter recordings (upper
right panel), QT dispersion (lower left panel), and QRS duration (lower right panel) measured by signal-averaged electrocardiogram (SAECG) among
the survivors and those who experienced a non-sudden cardiac death (SCD) or SCD during follow-up. All variables differed significantly between survivors
and those who had a non-SCD, although none of these variables differed between the survivors and those who experienced SCD.
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Potential limitations. A relatively small number of sudden
deaths (n  22) may prevent the generalization of the
results to other post-AMI populations. However, this is one
of the largest prospective, observational studies assessing the
prediction of sudden death in a consecutive post-AMI
population, including several predefined arrhythmia risk
markers in the study design. In the largest prospective,
observational study assessing the predictive power auto-
nomic markers, 30 patients reached the combined end point
of sudden death and nonfatal ventricular tachycardia (7). In
most of the previous observational studies, SCD and non-
fatal ventricular tachyarrhythmia have been used as a com-
bined end point (7,9,10,12,13,30). This end point is partly
biased, because many other conditions than arrhythmias
that evolve rapidly can also lead to sudden death. In fact,
recent studies on patients with an ICD indicate that many
of the deaths defined as sudden were not due to cardiac
arrhythmia (31,32). Therefore, we separately analyzed the
cases of SCD, defined by clinical criteria, and arrhythmia
events, defined by documentation of life-threatening ar-
rhythmia and/or autopsy findings. Despite the relatively low
number of SCDs and arrhythmia events in the current
study, the arrhythmia risk markers would have been ex-
pected to give a better predictive accuracy if they are
considered to be useful for clinical purposes (e.g., for
evaluation of the candidacy of an ICD).
The observational nature of the study design may not
allow definite conclusions about the clinical utility of the
arrhythmia risk variables. Therefore, the predictive power of
the arrhythmia risk markers should ideally be confirmed in
larger randomized trials, which should pay special attention
to adherence to evidence-based medical therapy, including
beta-blockers.
Conclusions. Common arrhythmia risk markers, particu-
larly the autonomic and standard ECG markers, seem to
lose some of their predictive power among patients
who are receiving beta-blocking therapy after AMI. Despite
the beta-blocking medication, still 3% of post-AMI
patients experienced SCD. These patients tended to have a
better functional capacity, despite left ventricular dysfunc-
tion, as compared with those who had a non-SCD. The
prediction and prevention of fatal arrhythmia events in these
patients still remain a challenge for future attempts to
reduce the unexpected deaths among patients surviving an
AMI.
Table 3. Arrhythmia Risk Variables as Predictors of SCD and
Arrhythmia Events
Hazard Ratio (95% CI)
SCD
(n  22)
Arrhythmia
Events
(n  17)
Univariate analysis
EF 0.40 2.7 (1.2–6.2)* 3.6 (1.4–9.4)†
Holter monitor
nsVT 4.2 (1.4–12.4)* 5.8 (1.9–18.0)†
VBPs 10/h 1.7 (0.6–4.7) 1.8 (0.6–5.8)
Autonomic markers
SDNN 70 ms 1.8 (0.7–4.7) 2.2 (0.7–6.7)
BRS 3.0 ms/mm Hg 1.2 (0.3–4.2) 1.0 (0.2–4.5)
ECG markers
Abnormal SAECG 5.4 (2.0–14.2)* 3.6 (1.0–12.9)*
12-lead ECG
QRS duration 120 ms 2.4 (0.8–7.0) 3.2 (1.0–9.8)*
QT dispersion 90 ms 1.0 (0.4–2.8) 2.0 (0.7–5.8)
Multivariate analysis§
EF 0.40 2.2 (1.0–9.3)* 3.2 (1.0–10.2)*
Holter monitor
nsVT 4.1 (1.3–13.0)† 7.4 (2.4–22.3)‡
VBPs 10/h 2.2 (0.6–8.7) 2.6 (0.9–9.2)
Autonomic markers
SDNN 70 ms 1.3 (0.5–3.8) 2.0 (0.7–6.2)
BRS 3.0 ms/mm Hg 0.9 (0.2–3.5) 0.7 (0.1–3.8)
ECG markers
Abnormal SAECG 4.6 (1.7–12.6)† 4.5 (1.3–15.4)*
12-lead ECG
QRS duration 120 ms 1.7 (0.6–5.3) 2.2 (0.7–7.0)
QT dispersion 90 ms 1.1 (0.4–3.0) 1.4(0.5–4.0)
*p  0.05, †p  0.01, ‡p  0.001. §Hazard ratio assessed by Cox regression analysis,
including age, diabetes, and NYHA class as co-variates.
CI  confidence interval; other abbreviations as in Tables 1 and 2.
Table 4. The Number of Patients With True-Positive, False-Negative, True-Negative, and
False-Positive Test Results
True-
Positive
False-
Negative
True-
Negative
False-
Positive
SCD
EF 0.40 10 (45%) 12 (55%) 442 (78%) 123 (22%)
nsVT 4 (19%) 17 (81%) 541 (95%) 29 (5%)
Abnormal SAECG 6 (32%) 13 (68%) 491 (92%) 42 (8%)
Non-SCD
EF 0.40 21 (58%) 15 (42%) 442 (78%) 123 (22%)
nsVT 5 (15%) 29 (85%) 541 (95%) 29 (5%)
Abnormal SAECG 9 (32%) 19 (68%) 491 (92%) 42 (8%)
Arrhythmia events
EF 0.40 8 (47%) 9 (53%) 442 (78%) 123 (22%)
nsVT 5 (31%) 11 (69%) 541 (95%) 29 (5%)
Abnormal SAECG 4 (29%) 10 (71%) 491 (92%) 42 (8%)
Data are presented as the number (%) of patients.
Abbreviations as in Table 2.
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